Exelixis stock

EXEL · NASDAQ · USD

Compare Exelixis
$68.50Change from previous close: +2.09%Absolute change: +$1.40

Close · November 17, 2026

Price history

+60.34% over the period

1 year: from $42.42 (November 17, 2025) to $68.02 (November 17, 2026), +60.34%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$68.02
October 30, 2026$69.39
September 30, 2026$58.41
August 31, 2026$54.64
July 31, 2026$53.03
June 30, 2026$54.41
May 29, 2026$50.48
April 30, 2026$44.46
March 31, 2026$42.89
February 27, 2026$44.06
January 30, 2026$41.36
December 31, 2025$43.83
November 28, 2025$44.17
November 17, 2025$42.42

At a glance

  • The company

    Develops and commercializes oncology medicines for difficult-to-treat cancers, including CABOMETYX and COTELLIC, in the United States

  • Latest results

    Quarter to September 30, 2026 · EPS $0.94 (estimate $0.87)

TickerLandia's take on Exelixis

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$39.71
52-wk high$73.69

−7.04% from the 52-week high

Analysts · 17 analysts

Average target$61.57−10.11% vs. price

Buy 6 · Hold 10 · Sell 1 · Buy

TickerLandia Fingerprint: Exelixis

Compared with similar companies: very strong momentum and very high profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Exelixis is priced as in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Exelixis's P/E today is 24.5, in line with the median of its last 9 fiscal years (25.4; between 8.80 and 62.0 from 2017 to 2025). Exelixis's P/E (trailing 12 months): 20.1, −60% against the median of a group of 8 similar companies (49.6).

P/E compared with its history

Compared with 8 similar companies

Exelixis's metrics compared with similar companies
MetricExelixisPosition in the groupBand
P/E (trailing 12 months)20.1Middle
Forward P/E15.7Middle
Operating margin40.2%High
ROE44.3%Middle
Debt/equity0.09Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Exelixis. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$658.7M

Latest quarter · Q3 2026

Net income

$218.1M

Latest quarter · Q3 2026

Quarterly net margin

33.1%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$16.37B
P/E
20.1
EPS
$3.34
Volume
2.68M
Daily trading
€182.55M
Dividend yield
0.00%

How Exelixis is changing

All results
  • Revenue grew 18.6% a year on average over the last 5 years

  • Operating margin rose from 12.5% to 37.6%

  • Profits turn into cash: free cash flow equal to 122% of net income

Returns

Exelixis returns

$1,000 invested in Exelixis 5 years ago, on November 17, 2021, would be worth $3,804 today: +280.40% in total, +30.64% per year. This is the price return only: dividends are excluded.

PeriodExelixisS&P 500$1,000 becomes
1 month+8.51%−3.17%$1,085
6 months+36.64%+0.11%$1,366
Year to date+55.18%+8.34%$1,552
1 year+60.34%+11.15%$1,603
3 years+221.89%+64.30%$3,219
5 years+280.40%+58.18%$3,804
10 years+306.06%+239.10%$4,061

Over the last 6 months it has done better than 75% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Exelixis: technical analysis

Exelixis is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.8% below its all-time closing high ($72.75, November 4, 2026).

Trend
Upward
RSI (14 sessions)
56
Between 30 and 70
vs 200-session average
+30.47%

Support and resistance

Price areas where Exelixis has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$68.50
  3. Support$59.44−13.23%2 touches, last on September 18, 2026
  4. Support$56.93−16.89%5 touches, last on October 6, 2026
  5. Support$54.01−21.16%5 touches, last on September 11, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.67
Volatility (60 sessions, annualised)
29.9%
Largest fall in the last year
−12.59%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Exelixis: seasonality

Average monthly price change over 27 years

+1.4%Jan+2.3%Feb−1.1%Mar+5.3%Apr+0.8%May+2.8%Jun+4.0%Jul−0.8%Aug−3.3%Sep+0.1%Oct+6.3%Nov+5.2%Dec

Over the last 27 years, the strongest month for Exelixis has been November: +6.31% on average, positive in 16 years out of 26. The weakest has been September: −3.34% on average, positive in 13 years out of 27.

Show chart data
MonthAverageMedianPositive years
January+1.44%+0.84%13 of 26
February+2.30%−0.75%13 of 26
March−1.13%−0.27%13 of 26
April+5.28%+3.51%15 of 26
May+0.85%−0.36%13 of 27
June+2.83%+3.60%16 of 27
July+3.96%+0.48%14 of 27
August−0.80%−0.53%13 of 27
September−3.34%−0.31%13 of 27
October+0.12%+1.75%15 of 27
November+6.31%+3.77%16 of 26
December+5.20%+4.58%16 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Exelixis and its competitors

Exelixis, Inc. is based in Alameda, California, and was founded in 1994. It is an oncology company focused on discovering, developing and commercializing medicines for difficult-to-treat cancers, with its revenue concentrated in the United States. Its products include CABOMETYX tablets for advanced renal cell carcinoma after prior anti-angiogenic therapy, COMETRIQ capsules for progressive and metastatic medullary thyroid cancer, COTELLIC for certain forms of advanced melanoma in combination, and MINNEBRO, offered for hypertension in Japan. Its pipeline includes zanzalintinib, XL309, XB010, XB628 and XB371.

Headquarters
Alameda, United States
Employees
1,077
Founded
1994
Chief executive
Michael Morrissey
Exelixis and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
ExelixisEXEL$16.37B40.2%20.1+36.64%
Jazz PharmaceuticalsJAZZ$15.5B27.4%71.5+5.22%
BridgeBio PharmaBBIO$15.25B-37.3%—+16.13%
Ascendis PharmaASND$18.06B30.9%18.1+12.76%
Halozyme TherapeuticsHALO$14.67B56.8%38.3+42.98%
BioNTechBNTX$21.22B-55.4%—−5.24%

Same industry or related industries, similar size. Compare Exelixis with its competitors · Full profile